You are here

Article Text

Article menu
Download PDFPDF
Short report
Tracing the footprints of MPXV in Asia: phylogenetic insights and lineage dynamics
  1. Yung-Chun Chen1,
  2. Yu-Chieh Liao2,
  3. Yan-Chiao Mao3,4,5,
  4. Ting-Kuang Yeh1,
  5. Po-Yu Liu1,5,6,7
  1. 1 Division of Infectious Diseases, Taichung Veterans General Hospital, Taichung, Taiwan
  2. 2 Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan
  3. 3 Division of Clinical Toxicology, Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
  4. 4 School of Medicine, National Defense Medical Center, Taichung, Taiwan
  5. 5 Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan
  6. 6 Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan
  7. 7 Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan
  1. Correspondence to Dr Po-Yu Liu, Taichung Veterans General Hospital, Taichung, Taiwan; pyliu{at}vghtc.gov.tw

Abstract

Objectives The 2022 global outbreak of monkeypox virus (MPXV), previously confined to Central and West Africa, necessitates an enhanced understanding of its spread. Comprehensive genomic surveillance to understand the virus’s evolution and spread is needed, particularly in Asia.

Methods Genomic data from 169 MPXV genome sequences in Asia were analysed. Through advanced genomic sequencing of clinical samples, we analysed the distribution and mutations of MPXV lineages in Asia.

Results Phylogenetic analysis revealed a distinct clustering of C.1 strains rise in Northeast Asia in 2023, while genomic examination identified specific consensus mutations like R84K, R665C and L16F in C.1 strains. The mutations, coupled with an increased rate of apolipoprotein B mRNA-editing catalytic polypeptide-like 3 motif G-to-A mutations in C.1 (OR 24.87±8.81), indicate a potential adaptation mechanism.

Conclusions Our findings underscore the need for ongoing surveillance and provide vital insights into MPXV’s evolving dynamics, aiding in public health strategy formulation against this emerging infectious threat.

  • Epidemiology
  • VIROLOGY
  • SEXUAL HEALTH

https://doi.org/10.1136/sextrans-2024-056119

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Apostolos Beloukas

    • Y-CC and Y-CL contributed equally.

    • Contributors Y-CC: conceptualisation, methodology, data curation, investigation, writing—original draft. Y-CL: conceptualisation, methodology, data curation, writing—original draft, writing—review and editing. Y-CM: conceptualisation, methodology, data curation, investigation. T-KY: writing—review and editing. P-YL: conceptualisation, methodology, data curation, investigation, writing—original draft, writing—review and editing.

    • Funding This work was supported by grant from National Health Research Institutes (PH-112-PP05) to Y-CL. National Science and Technology Council grant 112-2314-B-075A-006, Taichung Veterans General Hospital: TCVGH-1123901C, TCVGH-1123901D; TCVGH-PU1128105 to P-YL.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.